{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:38:17Z","timestamp":1794965897054,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The epigenome offers an additional facet of cancer that can help categorize patients into those at risk of disease, recurrence, or treatment failure. We conducted a retrospective, nested, case-control study of advanced and recurrent high-grade serous ovarian cancer (HGSOC) patients in which we assessed epigenome-wide association using Illumina methylationEPIC arrays to characterize DNA methylation status and RNAseq to evaluate gene expression. Comparing HGSOC tumors with normal fallopian tube tissues we observe global hypomethylation but with skewing towards hypermethylation when interrogating gene promoters. In total, 5,852 gene interrogating probes revealed significantly different methylation. Within HGSOC, 57 probes highlighting 17 genes displayed significant differential DNA methylation between primary and recurrent disease. Between optimal vs suboptimal surgical outcomes 99 probes displayed significantly different methylation but only 29 genes showed an inverse correlation between methylation status and gene expression. Overall, differentially methylated genes point to several pathways including RAS as well as hippo signaling in normal vs primary HGSOC; valine, leucine, and isoleucine degradation and endocytosis in primary vs recurrent HGSOC; and pathways containing immune driver genes in optimal vs suboptimal surgical outcomes. Thus, differential DNA methylation identified numerous genes that could serve as potential biomarkers and\/or therapeutic targets in HGSOC.<\/jats:p>","DOI":"10.1038\/s41598-019-54401-w","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T11:02:41Z","timestamp":1575025361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior"],"prefix":"10.1038","volume":"9","author":[{"given":"Henry D.","family":"Reyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-8604","authenticated-orcid":false,"given":"Eric J.","family":"Devor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshaya","family":"Warrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea M.","family":"Newtson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Mattson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle N.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly K.","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2079-4528","authenticated-orcid":false,"given":"Jesus","family":"Gonzalez-Bosquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"key":"54401_CR1","unstructured":"SEER Cancer Stat Facts: Ovarian Cancer, N. C. I. B., MD (2018)."},{"key":"54401_CR2","unstructured":"Cancer Facts and Figures 2018, Atlanta, GA: American Cancer Society (2018)."},{"key":"54401_CR3","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","volume":"97","author":"I Jacobs","year":"1990","unstructured":"Jacobs, I. et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 97, 922\u2013929, https:\/\/doi.org\/10.1111\/j.1471-0528.1990.tb02448.x (1990).","journal-title":"Br J Obstet Gynaecol"},{"key":"54401_CR4","doi-asserted-by":"publisher","first-page":"h4443","DOI":"10.1136\/bmj.h4443","volume":"351","author":"S Sundar","year":"2015","unstructured":"Sundar, S., Neal, R. D. & Kehoe, S. Diagnosis of ovarian cancer. BMJ (Clinical research ed.) 351, h4443, https:\/\/doi.org\/10.1136\/bmj.h4443 (2015).","journal-title":"BMJ (Clinical research ed.)"},{"key":"54401_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejogrb.2015.02.011","volume":"187","author":"N Rai","year":"2015","unstructured":"Rai, N. et al. Outcomes following implementation of symptom triggered diagnostic testing for ovarian cancer. European journal of obstetrics, gynecology, and reproductive biology 187, 64\u201369, https:\/\/doi.org\/10.1016\/j.ejogrb.2015.02.011 (2015).","journal-title":"European journal of obstetrics, gynecology, and reproductive biology"},{"key":"54401_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/s0140-6736(15)01224-6","volume":"387","author":"IJ Jacobs","year":"2016","unstructured":"Jacobs, I. J. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387, 945\u2013956, https:\/\/doi.org\/10.1016\/s0140-6736(15)01224-6 (2016).","journal-title":"Lancet"},{"key":"54401_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3892\/mco.2019.1800","volume":"10","author":"JL Hentze","year":"2019","unstructured":"Hentze, J. L., Hogdall, C. K. & Hogdall, E. V. Methylation and ovarian cancer: Can DNA methylation be of diagnostic use? Molecular and clinical oncology 10, 323\u2013330, https:\/\/doi.org\/10.3892\/mco.2019.1800 (2019).","journal-title":"Molecular and clinical oncology"},{"key":"54401_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid, B. M., Permuth, J. B. & Sellers, T. A. Epidemiology of ovarian cancer: a review. Cancer biology & medicine 14, 9\u201332, https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0084 (2017).","journal-title":"Cancer biology & medicine"},{"key":"54401_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.hoc.2018.07.003","volume":"32","author":"KM Elias","year":"2018","unstructured":"Elias, K. M., Guo, J. & Bast, R. C. Jr. Early Detection of Ovarian Cancer. Hematology\/oncology clinics of North America 32, 903\u2013914, https:\/\/doi.org\/10.1016\/j.hoc.2018.07.003 (2018).","journal-title":"Hematology\/oncology clinics of North America"},{"key":"54401_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. The New England journal of medicine 363, 943\u2013953, https:\/\/doi.org\/10.1056\/NEJMoa0908806 (2010).","journal-title":"The New England journal of medicine"},{"key":"54401_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe, S. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386, 249\u2013257, https:\/\/doi.org\/10.1016\/s0140-6736(14)62223-6 (2015).","journal-title":"Lancet"},{"key":"54401_CR12","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/jco.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L. & Montz, F. J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 20, 1248\u20131259, https:\/\/doi.org\/10.1200\/jco.2002.20.5.1248 (2002).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"54401_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1053\/j.seminoncol.2008.12.003","volume":"36","author":"LP Martin","year":"2009","unstructured":"Martin, L. P. & Schilder, R. J. Management of recurrent ovarian carcinoma: current status and future directions. Seminars in oncology 36, 112\u2013125, https:\/\/doi.org\/10.1053\/j.seminoncol.2008.12.003 (2009).","journal-title":"Seminars in oncology"},{"key":"54401_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-018-0602-0","volume":"11","author":"S Moufarrij","year":"2019","unstructured":"Moufarrij, S. et al. Epigenetic therapy for ovarian cancer: promise and progress. Clinical epigenetics 11, 7, https:\/\/doi.org\/10.1186\/s13148-018-0602-0 (2019).","journal-title":"Clinical epigenetics"},{"key":"54401_CR15","doi-asserted-by":"publisher","unstructured":"Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615, https:\/\/doi.org\/10.1038\/nature10166 (2011).","DOI":"10.1038\/nature10166"},{"key":"54401_CR16","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2217\/14622416.9.12.1825","volume":"9","author":"AJ Paige","year":"2008","unstructured":"Paige, A. J. & Brown, R. Pharmaco(epi)genomics in ovarian cancer. Pharmacogenomics 9, 1825\u20131834, https:\/\/doi.org\/10.2217\/14622416.9.12.1825 (2008).","journal-title":"Pharmacogenomics"},{"key":"54401_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones, P. A. & Baylin, S. B. The epigenomics of cancer. Cell 128, 683\u2013692, https:\/\/doi.org\/10.1016\/j.cell.2007.01.029 (2007).","journal-title":"Cell"},{"key":"54401_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41591-019-0376-8","volume":"25","author":"HP Mohammad","year":"2019","unstructured":"Mohammad, H. P., Barbash, O. & Creasy, C. L. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nature medicine 25, 403\u2013418, https:\/\/doi.org\/10.1038\/s41591-019-0376-8 (2019).","journal-title":"Nature medicine"},{"key":"54401_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrd.2016.256","volume":"16","author":"SX Pfister","year":"2017","unstructured":"Pfister, S. X. & Ashworth, A. Marked for death: targeting epigenetic changes in cancer. Nature reviews. Drug discovery 16, 241\u2013263, https:\/\/doi.org\/10.1038\/nrd.2016.256 (2017).","journal-title":"Nature reviews. Drug discovery"},{"issue":"3","key":"54401_CR20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/nu11030608","volume":"11","author":"Abeer Mahmoud","year":"2019","unstructured":"Mahmoud, A. M. & Ali, M. M. Methyl Donor Micronutrients that Modify DNA Methylation and Cancer Outcome. Nutrients 11, https:\/\/doi.org\/10.3390\/nu11030608 (2019).","journal-title":"Nutrients"},{"key":"54401_CR21","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman, J. G. & Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. The New England journal of medicine 349, 2042\u20132054, https:\/\/doi.org\/10.1056\/NEJMra023075 (2003).","journal-title":"The New England journal of medicine"},{"key":"54401_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ceb.2007.04.011","volume":"19","author":"M Weber","year":"2007","unstructured":"Weber, M. & Schubeler, D. Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Current opinion in cell biology 19, 273\u2013280, https:\/\/doi.org\/10.1016\/j.ceb.2007.04.011 (2007).","journal-title":"Current opinion in cell biology"},{"key":"54401_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/mmr.2014.2221","volume":"10","author":"O Koukoura","year":"2014","unstructured":"Koukoura, O., Spandidos, D. A., Daponte, A. & Sifakis, S. DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review). Molecular medicine reports 10, 3\u20139, https:\/\/doi.org\/10.3892\/mmr.2014.2221 (2014).","journal-title":"Molecular medicine reports"},{"key":"54401_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejogrb.2014.05.023","volume":"179","author":"MK Santillan","year":"2014","unstructured":"Santillan, M. K. et al. Collection of a lifetime: a practical approach to developing a longitudinal collection of women\u2019s healthcare biological samples. European journal of obstetrics, gynecology, and reproductive biology 179, 94\u201399, https:\/\/doi.org\/10.1016\/j.ejogrb.2014.05.023 (2014).","journal-title":"European journal of obstetrics, gynecology, and reproductive biology"},{"key":"54401_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/pcn.12835","volume":"73","author":"PR Braun","year":"2019","unstructured":"Braun, P. R. et al. Genome-wide DNA methylation investigation of glucocorticoid exposure within buccal samples. Psychiatry and clinical neurosciences 73, 323\u2013330, https:\/\/doi.org\/10.1111\/pcn.12835 (2019).","journal-title":"Psychiatry and clinical neurosciences"},{"key":"54401_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2199-7-3","volume":"7","author":"A Schroeder","year":"2006","unstructured":"Schroeder, A. et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC molecular biology 7, 3, https:\/\/doi.org\/10.1186\/1471-2199-7-3 (2006).","journal-title":"BMC molecular biology"},{"issue":"5","key":"54401_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3390\/ijms20051205","volume":"20","author":"Erin Salinas","year":"2019","unstructured":"Salinas, E. A. et al. A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables. International journal of molecular sciences 20, https:\/\/doi.org\/10.3390\/ijms20051205 (2019).","journal-title":"International Journal of Molecular Sciences"},{"key":"54401_CR28","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","volume":"30","author":"MJ Aryee","year":"2014","unstructured":"Aryee, M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics (Oxford, England) 30, 1363\u20131369, https:\/\/doi.org\/10.1093\/bioinformatics\/btu049 (2014).","journal-title":"Bioinformatics (Oxford, England)"},{"key":"54401_CR29","doi-asserted-by":"publisher","first-page":"E1004","DOI":"10.1210\/jc.2011-3298","volume":"97","author":"NS Rechache","year":"2012","unstructured":"Rechache, N. S. et al. DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. The Journal of clinical endocrinology and metabolism 97, E1004\u20131013, https:\/\/doi.org\/10.1210\/jc.2011-3298 (2012).","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"54401_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: an R package for comparing biological themes among gene clusters. Omics: a journal of integrative biology 16, 284\u2013287, https:\/\/doi.org\/10.1089\/omi.2011.0118 (2012).","journal-title":"Omics: a journal of integrative biology"},{"key":"54401_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00404-013-3041-3","volume":"289","author":"J Dietl","year":"2014","unstructured":"Dietl, J. Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube. Arch Gynecol Obstet 289, 241\u2013246, https:\/\/doi.org\/10.1007\/s00404-013-3041-3 (2014).","journal-title":"Arch Gynecol Obstet"},{"key":"54401_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy, S. I. et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nature communications 8, 1093, https:\/\/doi.org\/10.1038\/s41467-017-00962-1 (2017).","journal-title":"Nature communications"},{"key":"54401_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/his.12046","volume":"62","author":"R Vang","year":"2013","unstructured":"Vang, R., Shih, I. M. & Kurman, R. J. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 62, 44\u201358, https:\/\/doi.org\/10.1111\/his.12046 (2013).","journal-title":"Histopathology"},{"key":"54401_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ctrv.2018.06.004","volume":"69","author":"AA Gockley","year":"2018","unstructured":"Gockley, A. A. & Elias, K. M. Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction. Cancer treatment reviews 69, 66\u201371, https:\/\/doi.org\/10.1016\/j.ctrv.2018.06.004 (2018).","journal-title":"Cancer treatment reviews"},{"key":"54401_CR35","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1158\/1078-0432.ccr-04-2509","volume":"11","author":"RT Marquez","year":"2005","unstructured":"Marquez, R. T. et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clinical cancer research: an official journal of the American Association for Cancer Research 11, 6116\u20136126, https:\/\/doi.org\/10.1158\/1078-0432.ccr-04-2509 (2005).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"54401_CR36","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1158\/1541-7786.mcr-16-0097","volume":"14","author":"D Klinkebiel","year":"2016","unstructured":"Klinkebiel, D., Zhang, W., Akers, S. N., Odunsi, K. & Karpf, A. R. DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer. Molecular cancer research: MCR 14, 787\u2013794, https:\/\/doi.org\/10.1158\/1541-7786.mcr-16-0097 (2016).","journal-title":"Molecular cancer research: MCR"},{"key":"54401_CR37","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1200\/edbk_200203","volume":"38","author":"RN Eskander","year":"2018","unstructured":"Eskander, R. N. The Epigenetic Landscape in the Treatment of Gynecologic Malignancies. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 38, 480\u2013487, https:\/\/doi.org\/10.1200\/edbk_200203 (2018).","journal-title":"American Society of Clinical Oncology. Annual Meeting"},{"key":"54401_CR38","doi-asserted-by":"publisher","first-page":"6536","DOI":"10.1158\/1078-0432.CCR-18-1199","volume":"24","author":"TR Pisanic 2nd","year":"2018","unstructured":"Pisanic, T. R. 2nd et al. Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor Lesions. Clinical cancer research: an official journal of the American Association for. Cancer Research 24, 6536\u20136547, https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1199 (2018).","journal-title":"Cancer Research"},{"key":"54401_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11620","volume":"7","author":"TE Bartlett","year":"2016","unstructured":"Bartlett, T. E. et al. Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution. Nature communications 7, 11620, https:\/\/doi.org\/10.1038\/ncomms11620 (2016).","journal-title":"Nature communications"},{"key":"54401_CR40","doi-asserted-by":"publisher","first-page":"e8274","DOI":"10.1371\/journal.pone.0008274","volume":"4","author":"AE Teschendorff","year":"2009","unstructured":"Teschendorff, A. E. et al. An epigenetic signature in peripheral blood predicts active ovarian cancer. PloS one 4, e8274, https:\/\/doi.org\/10.1371\/journal.pone.0008274 (2009).","journal-title":"PloS one"},{"key":"54401_CR41","first-page":"2246","volume":"8","author":"SH Wei","year":"2002","unstructured":"Wei, S. H. et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clinical cancer research: an official journal of the American Association for. Cancer Research 8, 2246\u20132252 (2002).","journal-title":"Cancer Research"},{"key":"54401_CR42","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1158\/1078-0432.ccr-05-1551","volume":"12","author":"SH Wei","year":"2006","unstructured":"Wei, S. H. et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clinical cancer research: an official journal of the American Association for. Cancer Research 12, 2788\u20132794, https:\/\/doi.org\/10.1158\/1078-0432.ccr-05-1551 (2006).","journal-title":"Cancer Research"},{"key":"54401_CR43","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/j.1525-1438.2007.01117.x","volume":"18","author":"J Pattamadilok","year":"2008","unstructured":"Pattamadilok, J. et al. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society 18, 711\u2013717, https:\/\/doi.org\/10.1111\/j.1525-1438.2007.01117.x (2008).","journal-title":"International journal of gynecological cancer: official journal of the International Gynecological Cancer Society"},{"key":"54401_CR44","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1158\/0008-5472.can-13-3198","volume":"74","author":"C Wang","year":"2014","unstructured":"Wang, C. et al. Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer. Cancer research 74, 3084\u20133091, https:\/\/doi.org\/10.1158\/0008-5472.can-13-3198 (2014).","journal-title":"Cancer research"},{"key":"54401_CR45","doi-asserted-by":"publisher","first-page":"e76787","DOI":"10.1371\/journal.pone.0076787","volume":"8","author":"H Shi","year":"2013","unstructured":"Shi, H. et al. Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis. PloS one 8, e76787, https:\/\/doi.org\/10.1371\/journal.pone.0076787 (2013).","journal-title":"PloS one"},{"key":"54401_CR46","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4161\/epi.7.3.19273","volume":"7","author":"SL Samudio-Ruiz","year":"2012","unstructured":"Samudio-Ruiz, S. L. & Hudson, L. G. Increased DNA methyltransferase activity and DNA methylation following Epidermal Growth Factor stimulation in ovarian cancer cells. Epigenetics 7, 216\u2013224, https:\/\/doi.org\/10.4161\/epi.7.3.19273 (2012).","journal-title":"Epigenetics"},{"key":"54401_CR47","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41586-019-1219-y","volume":"569","author":"P Mauffrey","year":"2019","unstructured":"Mauffrey, P. et al. Progenitors from the central nervous system drive neurogenesis in cancer. Nature 569, 672\u2013678, https:\/\/doi.org\/10.1038\/s41586-019-1219-y (2019).","journal-title":"Nature"},{"key":"54401_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06640-0","volume":"9","author":"M Madeo","year":"2018","unstructured":"Madeo, M. et al. Cancer exosomes induce tumor innervation. Nature communications 9, 4284, https:\/\/doi.org\/10.1038\/s41467-018-06640-0 (2018).","journal-title":"Nature communications"},{"key":"54401_CR49","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41593-019-0430-3","volume":"22","author":"A Kamiya","year":"2019","unstructured":"Kamiya, A. et al. Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression. Nature neuroscience 22, 1289\u20131305, https:\/\/doi.org\/10.1038\/s41593-019-0430-3 (2019).","journal-title":"Nature neuroscience"},{"key":"54401_CR50","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1530\/erc-18-0243","volume":"25","author":"N Li","year":"2018","unstructured":"Li, N., Li, H., Cao, L. & Zhan, X. Quantitative analysis of the mitochondrial proteome in human ovarian carcinomas. Endocrine-related cancer 25, 909\u2013931, https:\/\/doi.org\/10.1530\/erc-18-0243 (2018).","journal-title":"Endocrine-related cancer"},{"key":"54401_CR51","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1158\/1538-7445.am2015-2236","volume":"75","author":"Z Huang","year":"2015","unstructured":"Huang, Z. et al. Emergence of epigenetic regulation of tight junction genes in recurrent serous epithelial ovarian cancer. Cancer research 75, 2236\u20132236, https:\/\/doi.org\/10.1158\/1538-7445.am2015-2236 (2015).","journal-title":"Cancer research"},{"key":"54401_CR52","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.canlet.2011.12.036","volume":"342","author":"BS Gloss","year":"2014","unstructured":"Gloss, B. S. & Samimi, G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer letters 342, 257\u2013263, https:\/\/doi.org\/10.1016\/j.canlet.2011.12.036 (2014).","journal-title":"Cancer letters"},{"key":"54401_CR53","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1158\/0008-5472.can-17-3480","volume":"78","author":"CW Wanderley","year":"2018","unstructured":"Wanderley, C. W. et al. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner. Cancer research 78, 5891\u20135900, https:\/\/doi.org\/10.1158\/0008-5472.can-17-3480 (2018).","journal-title":"Cancer research"},{"key":"54401_CR54","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.mayocp.2017.10.023","volume":"93","author":"MS Block","year":"2018","unstructured":"Block, M. S. et al. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic proceedings 93, 307\u2013320, https:\/\/doi.org\/10.1016\/j.mayocp.2017.10.023 (2018).","journal-title":"Mayo Clinic proceedings"},{"key":"54401_CR55","doi-asserted-by":"publisher","first-page":"e42413","DOI":"10.1371\/journal.pone.0042413","volume":"7","author":"J Chen","year":"2012","unstructured":"Chen, J. et al. SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. PloS one 7, e42413, https:\/\/doi.org\/10.1371\/journal.pone.0042413 (2012).","journal-title":"PloS one"},{"key":"54401_CR56","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1593\/neo.81146","volume":"11","author":"MJ Socha","year":"2009","unstructured":"Socha, M. J. et al. Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia (New York, N.Y.) 11, 126\u2013135, https:\/\/doi.org\/10.1593\/neo.81146 (2009).","journal-title":"Neoplasia (New York, N.Y.)"},{"key":"54401_CR57","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1158\/0008-5472.CAN-18-2297","volume":"79","author":"J Hooda","year":"2019","unstructured":"Hooda, J. et al. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer. Cancer research 79, 760\u2013772, https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2297 (2019).","journal-title":"Cancer research"},{"key":"54401_CR58","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1349-7006.2009.01434.x","volume":"101","author":"T Ushijima","year":"2010","unstructured":"Ushijima, T. & Asada, K. Aberrant DNA methylation in contrast with mutations. Cancer science 101, 300\u2013305, https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01434.x (2010).","journal-title":"Cancer science"},{"key":"54401_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrc1799","volume":"6","author":"SB Baylin","year":"2006","unstructured":"Baylin, S. B. & Ohm, J. E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nature reviews. Cancer 6, 107\u2013116, https:\/\/doi.org\/10.1038\/nrc1799 (2006).","journal-title":"Nature reviews. Cancer"},{"key":"54401_CR60","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.ygyno.2005.03.023","volume":"97","author":"G Strathdee","year":"2005","unstructured":"Strathdee, G. et al. Demethylation of the MCJ gene in stage III\/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol 97, 898\u2013903, https:\/\/doi.org\/10.1016\/j.ygyno.2005.03.023 (2005).","journal-title":"Gynecol Oncol"},{"key":"54401_CR61","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/ijc.25083","volume":"127","author":"HY Su","year":"2010","unstructured":"Su, H. Y. et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. International journal of cancer. Journal international du cancer 127, 555\u2013567, https:\/\/doi.org\/10.1002\/ijc.25083 (2010).","journal-title":"Journal international du cancer"},{"key":"54401_CR62","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/ijc.24546","volume":"125","author":"LJ Nicholson","year":"2009","unstructured":"Nicholson, L. J. et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. International journal of cancer. Journal international du cancer 125, 1454\u20131463, https:\/\/doi.org\/10.1002\/ijc.24546 (2009).","journal-title":"International journal of cancer. Journal international du cancer"},{"key":"54401_CR63","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1038\/sj.onc.1202540","volume":"18","author":"G Strathdee","year":"1999","unstructured":"Strathdee, G., MacKean, M. J., Illand, M. & Brown, R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18, 2335\u20132341, https:\/\/doi.org\/10.1038\/sj.onc.1202540 (1999).","journal-title":"Oncogene"},{"key":"54401_CR64","first-page":"139","volume":"29","author":"OW Yap","year":"2009","unstructured":"Yap, O. W., Bhat, G., Liu, L. & Tollefsbol, T. O. Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells. Anticancer Res 29, 139\u2013144 (2009).","journal-title":"Anticancer Res"},{"key":"54401_CR65","first-page":"1","volume":"36","author":"J Strauss","year":"2016","unstructured":"Strauss, J. & Figg, W. D. Using Epigenetic Therapy to Overcome Chemotherapy Resistance. Anticancer Res 36, 1\u20134 (2016).","journal-title":"Anticancer Res"},{"key":"54401_CR66","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/cncr.25701","volume":"117","author":"S Fu","year":"2011","unstructured":"Fu, S. et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117, 1661\u20131669, https:\/\/doi.org\/10.1002\/cncr.25701 (2011).","journal-title":"Cancer"},{"key":"54401_CR67","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1002\/cncr.25204","volume":"116","author":"F Fang","year":"2010","unstructured":"Fang, F. et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 116, 4043\u20134053, https:\/\/doi.org\/10.1002\/cncr.25204 (2010).","journal-title":"Cancer"},{"key":"54401_CR68","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/bjc.2014.116","volume":"110","author":"RM Glasspool","year":"2014","unstructured":"Glasspool, R. M. et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British journal of cancer 110, 1923\u20131929, https:\/\/doi.org\/10.1038\/bjc.2014.116 (2014).","journal-title":"British journal of cancer"},{"key":"54401_CR69","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.cd-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I. & D\u2019Andrea, A. D. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer discovery 5, 1137\u20131154, https:\/\/doi.org\/10.1158\/2159-8290.cd-15-0714 (2015).","journal-title":"Cancer discovery"},{"key":"54401_CR70","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1158\/1078-0432.ccr-03-0732","volume":"10","author":"G Gifford","year":"2004","unstructured":"Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B. & Brown, R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research 10, 4420\u20134426, https:\/\/doi.org\/10.1158\/1078-0432.ccr-03-0732 (2004).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54401-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54401-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54401-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:41:38Z","timestamp":1671295298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54401-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["54401"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-54401-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"assertion":[{"value":"16 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17996"}}